Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
Primary Purpose
Hyperthyroidism, Graves Disease, Atherosclerosis of Artery
Status
Completed
Phase
Phase 3
Locations
Indonesia
Study Type
Interventional
Intervention
Propylthiouracil
Methimazole
Sponsored by
About this trial
This is an interventional treatment trial for Hyperthyroidism focused on measuring Hyperthyroidism, Graves Disease, Atherosclerosis, Pathophysiology, Insulin Resistance, Lipid Marker, Inflammatory Marker, PWV, cIMT
Eligibility Criteria
Inclusion Criteria:
- Adult patients aged 18-65 years
- Newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month
- Agreed to participate in the study
Exclusion Criteria:
- Pregnancy
- History of coronary heart disease
- Known malignancy
- Current use of immunosuppressive medication sepsis, thyroid crisis
- Having allergic reaction to anti-thyroid drugs and other severe side effect
Sites / Locations
- University of Indonesia
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
PTU Group
Methimazole Group
Arm Description
Propylthiouracil (PTU) was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
Methimazole was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
Outcomes
Primary Outcome Measures
Pulse Wave Velocity
Pulse wave velocity was measured using radio frequency ultrasound in supine position at both left and right carotid artery
carotid intima media thickness
cIMT was measured using radio frequency ultrasound in supine position at both left and right carotid artery
Secondary Outcome Measures
HOMA-IR
HOMA-IR was calculated from patient fasting blood glucose and fasting insulin, which both were obtained through serum of the patient. Fasting blood glucose was measured using ECLIA methods with Abbott reagent, while fasting insulin were measured using ELISA with D&G International Inc. kit
LDL-R
LDL-R was measured from the patient serum using ELISA with D&G International Inc. kit
NFkB
NFkB was measured from the patient serum using ELISA with Cusabio kit
sICAM-1
sICAM-1 was measured from the patient serum using ELISA with D&G International Inc. kit
sVCAM-1
sVCAM-1 was measured from the patient serum using ELISA with D&G International Inc. kit
sE-selectin
sE-selectin was measured from the patient serum using ELISA with D&G International Inc. kit
Full Information
NCT ID
NCT05118542
First Posted
October 6, 2021
Last Updated
November 11, 2021
Sponsor
Indonesia University
1. Study Identification
Unique Protocol Identification Number
NCT05118542
Brief Title
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
Official Title
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
June 1, 2020 (Actual)
Study Completion Date
August 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole groups. There were 24 subjects who finished the study, 13 from PTU group and 11 from methimazole group. Blood serum was collected for HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin examination. Meanwhile stiffness and thickness of carotid artery was measured using PWV and cIMT.
Detailed Description
This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect. Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia with approval number KET-784/UN.2.F1/ETIK/PPM.00.02/2019.
Study participant was observed every month for 3 months. Anti-thyroid drugs (PTU or methimazole) were given according to true simple randomization with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist. At baseline visit, first and third month follow up, blood serum was collected to analyse HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin, meanwhile PWV and cIMT were measured using radiofrequency ultrasound examination of carotid arteries.
Categorical data was presented in frequency (%), while numerical data was presented using mean (SD) if normally distributed or median (IQR) if not normally distributed. Correlation Pearson test was performed for normal distributed data and Spearman test for not normal distributed data. To analyze the changes in parameter from baseline, first and third month, repeated ANOVA and General Linear Model test was performed. For not normally distributed data, transformation into normally distributed data was performed and the data was presented as geometric mean (CI 95%).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperthyroidism, Graves Disease, Atherosclerosis of Artery, Pathophysiology
Keywords
Hyperthyroidism, Graves Disease, Atherosclerosis, Pathophysiology, Insulin Resistance, Lipid Marker, Inflammatory Marker, PWV, cIMT
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect.
Masking
Care ProviderInvestigatorOutcomes Assessor
Masking Description
The care providers gave two choice of drug doses to the research assistant. The research assistant then give the participant their drugs based on the assignment from the randomisation.
The investigator and outcome assessor were blinded to the drugs which the participants received
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PTU Group
Arm Type
Active Comparator
Arm Description
Propylthiouracil (PTU) was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
Arm Title
Methimazole Group
Arm Type
Active Comparator
Arm Description
Methimazole was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
Intervention Type
Drug
Intervention Name(s)
Propylthiouracil
Intervention Description
PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
Intervention Type
Drug
Intervention Name(s)
Methimazole
Intervention Description
methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
Primary Outcome Measure Information:
Title
Pulse Wave Velocity
Description
Pulse wave velocity was measured using radio frequency ultrasound in supine position at both left and right carotid artery
Time Frame
Change from Baseline to 3 month follow-up
Title
carotid intima media thickness
Description
cIMT was measured using radio frequency ultrasound in supine position at both left and right carotid artery
Time Frame
Change from Baseline to 3 month follow-up
Secondary Outcome Measure Information:
Title
HOMA-IR
Description
HOMA-IR was calculated from patient fasting blood glucose and fasting insulin, which both were obtained through serum of the patient. Fasting blood glucose was measured using ECLIA methods with Abbott reagent, while fasting insulin were measured using ELISA with D&G International Inc. kit
Time Frame
Change from Baseline to 3 month follow-up
Title
LDL-R
Description
LDL-R was measured from the patient serum using ELISA with D&G International Inc. kit
Time Frame
Change from Baseline to 3 month follow-up
Title
NFkB
Description
NFkB was measured from the patient serum using ELISA with Cusabio kit
Time Frame
Change from Baseline to 3 month follow-up
Title
sICAM-1
Description
sICAM-1 was measured from the patient serum using ELISA with D&G International Inc. kit
Time Frame
Change from Baseline to 3 month follow-up
Title
sVCAM-1
Description
sVCAM-1 was measured from the patient serum using ELISA with D&G International Inc. kit
Time Frame
Change from Baseline to 3 month follow-up
Title
sE-selectin
Description
sE-selectin was measured from the patient serum using ELISA with D&G International Inc. kit
Time Frame
Change from Baseline to 3 month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients aged 18-65 years
Newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month
Agreed to participate in the study
Exclusion Criteria:
Pregnancy
History of coronary heart disease
Known malignancy
Current use of immunosuppressive medication sepsis, thyroid crisis
Having allergic reaction to anti-thyroid drugs and other severe side effect
Facility Information:
Facility Name
University of Indonesia
City
Jakarta Pusat
State/Province
Jakarta
ZIP/Postal Code
10430
Country
Indonesia
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
IPD would be share under specific request to the investigator
Citations:
PubMed Identifier
29089349
Citation
Bano A, Chaker L, Mattace-Raso FUS, van der Lugt A, Ikram MA, Franco OH, Peeters RP, Kavousi M. Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study. Circ Res. 2017 Dec 8;121(12):1392-1400. doi: 10.1161/CIRCRESAHA.117.311603. Epub 2017 Oct 31.
Results Reference
background
PubMed Identifier
21660244
Citation
Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011;5:76-84. doi: 10.2174/1874192401105010076. Epub 2011 Feb 24.
Results Reference
background
PubMed Identifier
21825964
Citation
Bilir C, Gokosmanoglu F, Caliskan M, Cinemre H, Akdemir R. Regression of the carotid intima media thickness by propylthiouracil therapy in Graves' hyperthyroidism. Am J Med Sci. 2012 Apr;343(4):273-6. doi: 10.1097/MAJ.0b013e31822a8284.
Results Reference
background
PubMed Identifier
12199623
Citation
Inaba M, Henmi Y, Kumeda Y, Ueda M, Nagata M, Emoto M, Ishikawa T, Ishimura E, Nishizawa Y. Increased stiffness in common carotid artery in hyperthyroid Graves' disease patients. Biomed Pharmacother. 2002 Jul;56(5):241-6. doi: 10.1016/s0753-3322(02)00195-6.
Results Reference
background
PubMed Identifier
27839806
Citation
Upala S, Wirunsawanya K, Jaruvongvanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017 Jan 15;227:338-341. doi: 10.1016/j.ijcard.2016.11.073. Epub 2016 Nov 9.
Results Reference
background
Learn more about this trial
Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis
We'll reach out to this number within 24 hrs